Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Comparative study of a mutant tissue-type plasminogen activator, YM866, with a tissue-type plasminogen activator in a canine model of femoral arterial thrombosis.

The Journal of pharmacy and pharmacology - 1 Oct 1996

Kawasaki T, Kaku S, Sakai Y, Takenaka T

Abstract excerpt

Because tissue-type plasminogen activator (tPA), used to treat myocardial infarction, has several disadvantages thought to be connected with its low half-life, mutants of tPA have been prepared with longer half-lives. We have compared the thrombolytic effect of such a mutant, YM866, with that of tPA in copper-coil-induced femoral arterial thrombosis in dogs. One hour after thrombus formation, YM866 was...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Blood Coagulation
Share to Dogs

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Fibrinolytic Agents

Share to Mutation

Share to Recombinant Proteins

Share to Thrombosis

Share to Tissue Plasminogen Activator

Source

Identifiers

PMID: 8953506
DOI: 10.1111/j.2042-7158.1996.tb05897.x

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Comparative study of a mutant tissue-type plasminogen activator, YM866, with a tissue-type plasminogen activator in a canine model of femoral arterial thrombosis.PMID 8953506Read ↗

Properties of a novel plasminogen activator (BM 06.022) produced in Escherichia coli.Semantic proximity Read ↗

Newer thrombolytic agents.Semantic proximity Read ↗

Thrombolysis vs. bleeding from hemostatic sites by a prourokinase mutant compared with tissue plasminogen activator.Semantic proximity Read ↗

Angiographic study of mutant tissue-type plasminogen activator versus urokinase for acute myocardial infarction.Semantic proximity Read ↗

Thrombolytic properties in a rabbit jugular vein thrombosis model of a tissue-type plasminogen activator mutant lacking the growth factor--and kringle one-domains.Semantic proximity Read ↗

Mutant prourokinase with adjunctive C1-inhibitor is an effective and safer alternative to tPA in rat stroke.Semantic proximity Read ↗

The potential improvement of thrombolytic therapy by targeting with bispecific monoclonal antibodies: why they are used and how they are made.Semantic proximity Read ↗

A first-in-human study of the anti-inflammatory profibrinolytic TMS-007, an SMTP family triprenyl phenolSemantic proximity Read ↗

Thrombolytic and pharmacokinetic properties of human tissue-type plasminogen activator variants, obtained by deletion and/or duplication of structural/functional domains, in a hamster pulmonary embolism model.Semantic proximity Read ↗

Plasminogen mutants activated by thrombin. Potential thrombus-selective thrombolytic agents.Semantic proximity Read ↗

Labeling of human clots in vitro with an active-site mutant of t-PA.Semantic proximity Read ↗

Studies on the regulation of tissue plasminogen activator activity by physiological templatesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.